Corcept Therapeutics Faces Investigation After FDA Response Letter, Shares Plunge Over 50%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy CORT?
Source: Businesswire
- Investigation Launched: DJS Law Group is investigating Corcept Therapeutics for potential violations of securities laws, focusing on whether the company issued misleading statements or failed to disclose critical information to investors, which could undermine investor confidence.
- FDA Response Letter: On December 31, 2026, Corcept revealed that the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, indicating that the company must provide additional evidence of effectiveness, impacting the drug's market prospects.
- Clinical Trial Results: Although the FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial provided confirmatory evidence, the agency could not arrive at a favorable benefit-risk assessment for relacorilant, highlighting regulatory hurdles.
- Stock Price Plunge: Following the negative FDA news, Corcept's shares plummeted by over 50%, resulting in significant losses for investors and potentially triggering further legal actions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 41.980
Low
50.00
Averages
91.00
High
121.00
Current: 41.980
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging investors who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: During the Class Period from 2024 to 2025, Corcept is accused of failing to disclose serious FDA concerns regarding the efficacy data of its lead drug candidate, relacorilant, leading to investor misconceptions about the company's prospects.
- Stock Price Crash: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market disappointment in the company's outlook.
- Information Gap Issue: Hagens Berman partner Reed Kathrein highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, potentially impacting investors' future decision-making based on inaccurate perceptions of the company's operational status.
See More
Corcept Faces Securities Class Action Lawsuit
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Corcept shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to secure their rights in the class action lawsuit.
- Legal Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the approval prospects of their lead drug candidate, relacorilant.
- FDA Response Letter: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter for relacorilant's NDA, indicating that additional evidence was required to assess its effectiveness, which adversely affected the company's reputation and stock price.
- Stock Price Plunge: Following the FDA announcement, Corcept's stock price plummeted from $70.20 on December 30, 2025, to $34.80, a decline of 50.4%, reflecting market pessimism regarding the company's future prospects.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Lawsuit Background: The lawsuit, filed by the Allegheny County Employees' Retirement System, targets all investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, seeking to recover losses incurred during this period.
- Disclosure Failures: The complaint alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose critical information reportedly communicated by the FDA, which has led to significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as the new SEC Whistleblower program offers rewards of up to 30% of any successful recovery, thereby enhancing the case's potential for success.
See More
Multiple Companies Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. faces a class action lawsuit for materially misstated financial statements and inadequate internal controls during the period from August 2024 to February 2026, which severely undermines investor confidence and could negatively impact its stock performance.
- PayPal Lawsuit Details: PayPal Holdings, Inc. is accused in a class action lawsuit from February 2025 to February 2026 of overstating its business execution capabilities and dismissing competitive concerns, leading to a decline in investor trust and potential adverse effects on its market share.
- NuScale Lawsuit Background: NuScale Power Corporation is facing a class action lawsuit for failing to disclose significant risks associated with its nuclear projects during the period from May 2025 to November 2025, which could jeopardize its commercialization strategy and affect future financing and project timelines.
- Corcept Lawsuit Issues: Corcept Therapeutics Incorporated is under scrutiny in a class action lawsuit from October 2024 to January 2026 for not meeting FDA requirements regarding the effectiveness assessment of its drug, which may lead to significant review challenges for its new drug application and impact the company's future competitiveness.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 to $34.80 after the FDA rejected its new drug application, indicating a significant loss of investor confidence in the company's future prospects.
- Legal Allegations Context: The lawsuit alleges that Corcept and its executives failed to disclose material information during the class period, violating federal securities laws, which suggests a potential breach of fiduciary duty that could lead to substantial investor losses.
- Law Firm's Role: Kahn Swick & Foti, LLC, representing the plaintiffs, specializes in recovering losses for investors due to corporate fraud or misconduct, demonstrating its expertise and influence in the securities litigation landscape.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026, urging investors to contact the firm promptly to protect their rights.
- False Statements Allegation: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose significant FDA concerns regarding the effectiveness data of its lead drug candidate, Relacorilant, resulting in substantial investor losses.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day.
- Information Gap Issue: The heart of the case lies in the significant discrepancy between the information the company publicly disclosed and what the FDA reportedly communicated privately, leading to investor misjudgments about the company's prospects and impacting market confidence.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging investors who suffered significant losses to contact the firm promptly to protect their rights.
- False Statements Allegation: During the Class Period from 2024 to 2025, Corcept is accused of failing to disclose serious FDA concerns regarding the efficacy data of its lead drug candidate, relacorilant, leading to investor misconceptions about the company's prospects.
- Stock Price Crash: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting extreme market disappointment in the company's outlook.
- Information Gap Issue: Hagens Berman partner Reed Kathrein highlighted that there is a significant information gap between what Corcept publicly stated and what the FDA communicated privately, potentially impacting investors' future decision-making based on inaccurate perceptions of the company's operational status.
See More
Corcept Faces Securities Class Action Lawsuit
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Corcept shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to secure their rights in the class action lawsuit.
- Legal Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the approval prospects of their lead drug candidate, relacorilant.
- FDA Response Letter: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter for relacorilant's NDA, indicating that additional evidence was required to assess its effectiveness, which adversely affected the company's reputation and stock price.
- Stock Price Plunge: Following the FDA announcement, Corcept's stock price plummeted from $70.20 on December 30, 2025, to $34.80, a decline of 50.4%, reflecting market pessimism regarding the company's future prospects.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds investors in Corcept Therapeutics that the deadline to apply for Lead Plaintiff status is April 21, 2026, urging affected investors to contact the firm promptly to protect their rights.
- Lawsuit Background: The lawsuit, filed by the Allegheny County Employees' Retirement System, targets all investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, seeking to recover losses incurred during this period.
- Disclosure Failures: The complaint alleges that Corcept made materially false and misleading statements regarding its lead drug candidate, Relacorilant, by failing to disclose critical information reportedly communicated by the FDA, which has led to significant investor losses.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to assist in the investigation, as the new SEC Whistleblower program offers rewards of up to 30% of any successful recovery, thereby enhancing the case's potential for success.
See More
Multiple Companies Face Class Action Lawsuits
- Kyndryl Lawsuit Overview: Kyndryl Holdings, Inc. faces a class action lawsuit for materially misstated financial statements and inadequate internal controls during the period from August 2024 to February 2026, which severely undermines investor confidence and could negatively impact its stock performance.
- PayPal Lawsuit Details: PayPal Holdings, Inc. is accused in a class action lawsuit from February 2025 to February 2026 of overstating its business execution capabilities and dismissing competitive concerns, leading to a decline in investor trust and potential adverse effects on its market share.
- NuScale Lawsuit Background: NuScale Power Corporation is facing a class action lawsuit for failing to disclose significant risks associated with its nuclear projects during the period from May 2025 to November 2025, which could jeopardize its commercialization strategy and affect future financing and project timelines.
- Corcept Lawsuit Issues: Corcept Therapeutics Incorporated is under scrutiny in a class action lawsuit from October 2024 to January 2026 for not meeting FDA requirements regarding the effectiveness assessment of its drug, which may lead to significant review challenges for its new drug application and impact the company's future competitiveness.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 to $34.80 after the FDA rejected its new drug application, indicating a significant loss of investor confidence in the company's future prospects.
- Legal Allegations Context: The lawsuit alleges that Corcept and its executives failed to disclose material information during the class period, violating federal securities laws, which suggests a potential breach of fiduciary duty that could lead to substantial investor losses.
- Law Firm's Role: Kahn Swick & Foti, LLC, representing the plaintiffs, specializes in recovering losses for investors due to corporate fraud or misconduct, demonstrating its expertise and influence in the securities litigation landscape.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds Corcept Therapeutics shareholders that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026, urging investors to contact the firm promptly to protect their rights.
- False Statements Allegation: Throughout the Class Period from 2024 to 2025, Corcept is accused of failing to disclose significant FDA concerns regarding the effectiveness data of its lead drug candidate, Relacorilant, resulting in substantial investor losses.
- Stock Price Crash: On December 31, 2025, Corcept revealed it received a Complete Response Letter from the FDA, causing its stock price to plummet from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day.
- Information Gap Issue: The heart of the case lies in the significant discrepancy between the information the company publicly disclosed and what the FDA reportedly communicated privately, leading to investor misjudgments about the company's prospects and impacting market confidence.
See More
